Proteomics-based Research Initiative for Non-CYP Enzymes (PRINCE)

The PRINCE (Proteomics-based Research Initiative for Non-CYP Enzymes) program is a research collaboration between the University of Washington and pharmaceutical industry to elucidate role of non-cytochrome P450 (non-CYP) enzymes in disposition, efficacy and toxicity of drugs.

Overarching Objective: Characterization of subcellular localization, differential tissue expression and interindividual variability of non-CYP enzymes to develop whole body based physiological (i.e., PBPK) models to predict drug disposition

Specific goals (Year 1):

Aim 1: To characterize differential tissue abundance (using quantitative proteomics) of non-CYP enzymes listed below in human intestine, kidney, heart, lung and liver by LC-MS/MS

Enzymes to be studied: UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, UGT2B15, UGT2B17, UGT2B4, AOX, CES1 and CES2

Aim 2: To characterize intestinal abundance of above non-CYP enzymes in intestinal microsomes, tissue and enterocytes from the paired donors by LC-MS/MS proteomics.

Aim 3: Preliminary LC-MS/MS method development for animal non-CYP enzymes.

Industry Members:

  • Genentech
  • Gilead
  • Merck 


Bhagwat Prasad, Ph.D.
Role: Program Director

Naveen Neradugomma, Ph.D.
Role: Lead Scientist

Abdul Basit, Ph.D.,
Role: Technical Director, Mass Spectrometry

Mathew T. Karasu
Role: Research Scientist


Please contact Bhagwat Prasad if you are interested to become PRINCE member or have any questions regarding this program.

Shipping address:
Attn: Matt Karasu
1959 NE Pacific St
Seattle, WA